CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Aldeyra Therapeutics, Inc. - ALDX CFD

    3.25
    14.84%
    0.05
    Low: 2.92
    High: 3.33
    Market Trading Hours* (UTC) Opens on Tuesday at 14:30

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Aldeyra Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 2.83
    Open* 2.92
    1-Year Change* -55.01%
    Day's Range* 2.92 - 3.33
    52 wk Range 1.42-11.97
    Average Volume (10 days) 1.41M
    Average Volume (3 months) 54.08M
    Market Cap 143.53M
    P/E Ratio -100.00K
    Shares Outstanding 58.82M
    Revenue N/A
    EPS -0.78
    Dividend (Yield %) N/A
    Beta 1.30
    Next Earnings Date Mar 7, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 2.83 0.06 2.17% 2.77 2.87 2.67
    Nov 30, 2023 2.76 0.00 0.00% 2.76 2.88 2.75
    Nov 29, 2023 2.74 0.06 2.24% 2.68 2.93 2.68
    Nov 28, 2023 2.68 0.18 7.20% 2.50 2.70 2.45
    Nov 27, 2023 2.59 0.10 4.02% 2.49 2.60 2.41
    Nov 24, 2023 2.50 -0.02 -0.79% 2.52 2.63 2.49
    Nov 22, 2023 2.49 0.06 2.47% 2.43 2.60 2.42
    Nov 21, 2023 2.42 -0.24 -9.02% 2.66 2.69 2.42
    Nov 20, 2023 2.63 -0.14 -5.05% 2.77 2.84 2.61
    Nov 17, 2023 2.83 0.37 15.04% 2.46 2.90 2.45
    Nov 16, 2023 2.46 -0.06 -2.38% 2.52 2.55 2.41
    Nov 15, 2023 2.50 -0.03 -1.19% 2.53 2.67 2.49
    Nov 14, 2023 2.55 0.08 3.24% 2.47 2.56 2.44
    Nov 13, 2023 2.43 0.15 6.58% 2.28 2.43 2.21
    Nov 10, 2023 2.26 -0.08 -3.42% 2.34 2.34 2.18
    Nov 9, 2023 2.33 -0.22 -8.63% 2.55 2.58 2.30
    Nov 8, 2023 2.59 -0.08 -3.00% 2.67 2.87 2.50
    Nov 7, 2023 2.74 0.48 21.24% 2.26 2.74 2.24
    Nov 6, 2023 2.24 0.03 1.36% 2.21 2.41 2.18
    Nov 3, 2023 2.18 0.09 4.31% 2.09 2.24 2.05

    Aldeyra Therapeutics, Inc. Events

    Time (UTC) Country Event
    Thursday, March 7, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Aldeyra Therapeutics Inc Earnings Release
    Q4 2023 Aldeyra Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Revenue
    Total Operating Expense 62.68 56.2195 36.421 63.0743 39.6992
    Selling/General/Admin. Expenses, Total 15.3739 11.283 9.98545 12.1547 9.87614
    Research & Development 47.3061 44.9365 24.6813 44.3518 29.823
    Operating Income -62.68 -56.2195 -36.421 -63.0743 -39.6992
    Interest Income (Expense), Net Non-Operating 0.65535 -1.55674 -1.61198 0.9375 0.80591
    Net Income Before Taxes -62.0246 -57.7763 -38.033 -62.1368 -38.8932
    Net Income After Taxes -62.0246 -57.7763 -37.5537 -60.8268 -38.8932
    Net Income Before Extra. Items -62.0246 -57.7763 -37.5537 -60.8268 -38.8932
    Net Income -62.0246 -57.7763 -37.5537 -60.8268 -38.8932
    Income Available to Common Excl. Extra. Items -62.0246 -57.7763 -37.5537 -60.8268 -38.8932
    Income Available to Common Incl. Extra. Items -62.0246 -57.7763 -37.5537 -60.8268 -38.8932
    Diluted Net Income -62.0246 -57.7763 -37.5537 -60.8268 -38.8932
    Diluted Weighted Average Shares 58.4059 54.0421 33.966 27.1118 21.6856
    Diluted EPS Excluding Extraordinary Items -1.06196 -1.0691 -1.10563 -2.24355 -1.7935
    Diluted Normalized EPS -1.06196 -1.0691 -1.05398 -2.00131 -1.7935
    Unusual Expense (Income) 0 1.75427 6.56775
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 10.3427 16.8033 13.6968 14.7846 17.7149
    Selling/General/Admin. Expenses, Total 3.37975 5.56742 4.73532 3.24494 3.14428
    Research & Development 6.96291 11.2359 8.96147 11.5396 14.5707
    Operating Income -10.3427 -16.8033 -13.6968 -14.7846 -17.7149
    Interest Income (Expense), Net Non-Operating 1.35566 1.1876 0.79463 0.23132 -0.06602
    Net Income Before Taxes -8.987 -15.6157 -12.9022 -14.5532 -17.781
    Net Income After Taxes -8.987 -15.6157 -12.9022 -14.5532 -17.781
    Net Income Before Extra. Items -8.987 -15.6157 -12.9022 -14.5532 -17.781
    Net Income -8.987 -15.6157 -12.9022 -14.5532 -17.781
    Income Available to Common Excl. Extra. Items -8.987 -15.6157 -12.9022 -14.5532 -17.781
    Income Available to Common Incl. Extra. Items -8.987 -15.6157 -12.9022 -14.5532 -17.781
    Diluted Net Income -8.987 -15.6157 -12.9022 -14.5532 -17.781
    Diluted Weighted Average Shares 58.7919 58.7916 58.5646 58.4579 58.3015
    Diluted EPS Excluding Extraordinary Items -0.15286 -0.26561 -0.22031 -0.24895 -0.30498
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.15286 -0.26561 -0.22031 -0.24895 -0.30498
    Unusual Expense (Income)
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 181.023 232.753 83.0593 75.1688 94.7693
    Cash and Short Term Investments 174.301 229.791 77.8583 73.3644 93.5997
    Cash & Equivalents 9.26828 129.426 54.3634 29.0624 45.2303
    Short Term Investments 29.8815 0 28.9386 46.2422
    Prepaid Expenses 6.72223 2.96178 5.20096 1.80445 1.16959
    Total Assets 181.292 233.137 83.3525 75.5183 95.0912
    Property/Plant/Equipment, Total - Net 0.26854 0.38435 0.29324 0.34946 0.23523
    Other Long Term Assets, Total 0 0.08664
    Total Current Liabilities 15.3605 11.7727 12.4095 12.9078 8.47318
    Accounts Payable 0.13363 1.0197 0.38164 0.8083 3.05168
    Accrued Expenses 14.3152 10.753 8.36808 12.0995 5.4215
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.91176 0 3.65978 0
    Total Liabilities 30.2836 27.4016 23.844 27.436 8.47318
    Total Long Term Debt 14.9231 15.5037 11.4345 14.5282 0
    Long Term Debt 14.9231 15.5037 11.4345 14.5282 0
    Total Equity 151.008 205.736 59.5086 48.0823 86.618
    Common Stock 0.05856 0.05808 0.03867 0.02866 0.02624
    Additional Paid-In Capital 507.77 500.369 296.386 247.41 225.136
    Retained Earnings (Accumulated Deficit) -356.717 -294.692 -236.916 -199.362 -138.535
    Other Equity, Total -0.10394 0 0 0.00587 -0.00922
    Total Liabilities & Shareholders’ Equity 181.292 233.137 83.3525 75.5183 95.0912
    Total Common Shares Outstanding 58.5601 58.0812 38.6675 28.6568 26.2444
    Cash 135.151 100.365 23.4949 15.3635 2.12718
    Other Liabilities, Total 0 0.12523
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 147.21 155.479 168.017 181.023 189.483
    Cash and Short Term Investments 143.335 151.676 165.028 174.301 185.329
    Cash & Equivalents 46.5314 40.1714 39.7152 9.26828 22.1109
    Prepaid Expenses 3.87513 3.80356 2.98912 6.72223 4.15372
    Other Current Assets, Total
    Total Assets 147.282 155.616 168.219 181.292 189.692
    Property/Plant/Equipment, Total - Net 0.07223 0.13723 0.20157 0.26854 0.2086
    Total Current Liabilities 21.6173 15.6051 16.0079 15.3605 24.195
    Accounts Payable 0.24719 0.27082 0.42969 0.13363 1.30693
    Accrued Expenses 7.90902 9.43998 14.6239 14.3152 10.439
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 13.4611 5.89432 0.95433 0.91176 12.4491
    Total Liabilities 24.2745 25.7332 30.9756 30.2836 27.4981
    Total Long Term Debt 2.65719 10.128 14.9677 14.9231 3.30304
    Long Term Debt 2.65719 10.128 14.9677 14.9231 3.30304
    Total Equity 123.008 129.883 137.243 151.008 162.194
    Common Stock 0.05919 0.0588 0.05879 0.05856 0.05856
    Additional Paid-In Capital 512.455 511.144 509.517 507.77 506.235
    Retained Earnings (Accumulated Deficit) -389.506 -381.319 -372.332 -356.717 -343.814
    Total Liabilities & Shareholders’ Equity 147.282 155.616 168.219 181.292 189.692
    Total Common Shares Outstanding 59.1873 58.8012 58.7916 58.5601 58.5601
    Cash 96.8035 111.504 125.313 135.151 106.54
    Other Equity, Total 0 0 0 -0.10394 -0.28573
    Other Liabilities, Total 0 0
    Short Term Investments 0 0 0 29.8815 56.6789
    Redeemable Preferred Stock 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -62.0246 -57.7763 -37.5537 -60.8268 -38.8932
    Cash From Operating Activities -56.6372 -42.5559 -37.4935 -44.9842 -29.8571
    Cash From Operating Activities 0.25871 0.26418 0.05622 0.09631 0.071
    Non-Cash Items 8.57288 7.5175 9.31286 14.3154 3.96663
    Cash Interest Paid 1.33854 1.33708 1.38775 0.23849 0.08896
    Changes in Working Capital -3.44414 7.43869 -8.82955 2.7409 4.99848
    Cash From Investing Activities -29.9545 -0.00781 29.0239 18.4769 -23.3356
    Capital Expenditures -0.01632 -0.00781 0 -0.00953 -0.26297
    Other Investing Cash Flow Items, Total -29.9382 0 29.0239 18.4864 -23.0726
    Cash From Financing Activities 1.22009 194.496 41.902 23.5757 80.5268
    Financing Cash Flow Items 0.09667 0.06153 0.12697 0.07166 0
    Issuance (Retirement) of Stock, Net 1.12343 194.435 41.7751 9.05407 81.9227
    Net Change in Cash -85.3716 151.933 33.4325 -2.93164 27.3341
    Issuance (Retirement) of Debt, Net 0 14.45 -1.39583
    Deferred Taxes 0 -0.47927 -1.30997
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -15.6157 -62.0246 -49.1225 -34.5692 -16.7883
    Cash From Operating Activities -9.44382 -56.6372 -45.406 -32.8318 -12.8732
    Cash From Operating Activities 0.06697 0.25871 0.19206 0.12675 0.06274
    Non-Cash Items 4.26297 8.57288 5.6897 3.3879 2.01615
    Cash Interest Paid 0.3974 1.33854 0.98183 0.65217 0.3225
    Changes in Working Capital 1.84192 -3.44414 -2.1653 -1.7772 1.8362
    Cash From Investing Activities 30 -29.9545 -56.9545 -75.9705 -58.0318
    Capital Expenditures 0 -0.01632 -0.01632 -0.01632 -0.01632
    Cash From Financing Activities 0.05256 1.22009 1.22009 0.02332 0.02332
    Financing Cash Flow Items 0.05256 0.09667 0.09667 0.02332 0.02332
    Issuance (Retirement) of Stock, Net 1.12343 1.12343 0 0
    Net Change in Cash 20.6087 -85.3716 -101.14 -108.779 -70.8817
    Other Investing Cash Flow Items, Total 30 -29.9382 -56.9382 -75.9542 -58.0155
    Deferred Taxes
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Perceptive Advisors LLC Private Equity 14.1428 8287087 -3062998 2023-10-18 MED
    Knoll Capital Management, LLC Hedge Fund 6.1368 3595916 580248 2023-10-04
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.4134 3172057 672896 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 5.1913 3041866 2868585 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 5.0676 2969388 2003542 2023-06-30 LOW
    Brady (Todd C) Individual Investor 1.9498 1142476 199251 2023-09-07 LOW
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.921 1125645 2737 2023-06-30 LOW
    Eagle Asset Management, Inc. Investment Advisor/Hedge Fund 1.8065 1058546 -785464 2023-06-30 LOW
    Laurion Capital Management LP Hedge Fund 1.709 1001377 44477 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.6268 953250 464905 2023-06-30 LOW
    Verition Fund Management LLC Hedge Fund 1.5873 930074 -634954 2023-06-30 HIGH
    Fidelity Management & Research Company LLC Investment Advisor 1.1626 681258 -107531 2023-06-30 LOW
    Two Sigma Investments, LP Hedge Fund 0.9647 565300 -183100 2023-06-30 HIGH
    Millennium Management LLC Hedge Fund 0.8458 495575 -622856 2023-06-30 HIGH
    Invesco Capital Management LLC Investment Advisor 0.8377 490845 208139 2023-06-30 LOW
    Johnson & Johnson Innovation-JJDC, Inc. Venture Capital 0.6738 394834 0 2023-06-30 LOW
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.6334 371130 286468 2023-06-30 LOW
    Renaissance Technologies LLC Hedge Fund 0.5211 305356 57956 2023-06-30 HIGH
    Wells Fargo Advisors Research Firm 0.4741 277776 6261 2023-06-30 LOW
    DWS Investment GmbH Investment Advisor/Hedge Fund 0.4558 267064 43010 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Aldeyra Therapeutics, Inc. Company profile

    About Aldeyra Therapeutics Inc

    Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in developing immune-modulating therapies to treat ocular and systemic diseases. The Company's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). It has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The Company's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses three biological mechanisms of action: reactive aldehyde species (RASP) inhibition, dihydrofolate reductase (DHFR) inhibition, and protein chaperome (CHP) inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation via down-regulation of immune cell activation or proliferation.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 54% to $57.8M. Higher net loss reflects Research and development increase of 98% to $41.4M (expense), General and administrative increase of 15% to $7.7M (expense), General and administrative expenses increase of 8% to $3.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.11 to -$1.07.

    Industry: Bio Therapeutic Drugs

    131 Hartwell Avenue
    Suite 320
    LEXINGTON
    MASSACHUSETTS 02421
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    US100

    15,804.70 Price
    -1.170% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    BTC/USD

    41,777.50 Price
    +4.930% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    XRP/USD

    0.63 Price
    +0.090% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Oil - Crude

    73.29 Price
    -1.420% 1D Chg, %
    Long position overnight fee -0.0200%
    Short position overnight fee -0.0019%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading